Thomlinson R H, Dische S, Gray A J, Errington L M
Clin Radiol. 1976 Apr;27(2):167-74. doi: 10.1016/s0009-9260(76)80139-0.
The nitro-imidazole Ro-07-0582, a known radiosensitiser of hypoxic cells in animals, was administered orally to seven patients with metastatic tumour, before irradiation. The delay imposed on the growth of tumour treated in this way was compared to that of tumour in the same patient treated with radiation alone. Two patients died before any assessment of response could be made. Qualitative evidence from a further three patients suggested some enhancement of radiation effect in two patients but not in the third. Quantitative evidence was obtained from the remaining two patients. In one, a patient with multiple pulmonary metastases from a carcinoma of the breast, no enhancement was shown. In the other, a patient in whom 21 subcutaneous metastases from a carcinoms of the cervix of the uterus were measured, an enhancement ratio of 1-2 was found. This agrees with the value from the same patient's skin when rendered artificially hypoxic, as reported previously. The conditions under which quantitative information may best be obtained in this type of trial are described and various factors affecting the interpretation of results are discussed. Ro-07-0582 has thus been shown to have a radiosensitising effect in man and may therefore prove of value in radiotherapy.
硝基咪唑Ro-07-0582是一种已知的动物低氧细胞放射增敏剂，在放疗前对7例转移性肿瘤患者进行口服给药。将以此方式治疗的肿瘤生长延迟情况与同一患者单纯接受放疗的肿瘤生长延迟情况进行比较。有2例患者在能够进行任何反应评估之前死亡。另外3例患者的定性证据表明，2例患者的放射效应有所增强，而第3例患者则没有。从其余2例患者获得了定量证据。其中1例为乳腺癌多发肺转移患者，未显示出增强效果。另1例患者测量了子宫颈癌的21个皮下转移灶，发现增强比为1.2。这与先前报道的同一患者皮肤人为造成低氧时的值相符。描述了在此类试验中最有可能获得定量信息的条件，并讨论了影响结果解释的各种因素。因此，Ro-07-0582已被证明对人体有放射增敏作用，因此可能在放射治疗中具有价值。
